Skip to main content
K

Will the FDA approve MDMA for PTSD?

Event Group
EventKALSHI
Will the FDA approve MDMA for PTSD?
Will the FDA approve MDMA for PTSD?
|
Vol

13.7K contracts

|
Markets

6

Market snapshot: Nov 22, 2026, 12:00 PM UTC. Prices may have changed.

Market Price Graph

6 markets tracked

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?

kalshi

No data available

All Markets(6)
MarketOutcome price
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?
Yes 54.0%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?
Yes 53.0%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?
Yes 52.0%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?
Yes 51.5%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2028?
Yes 42.5%

Event Overview

MDMA for PTSD If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application, ANDA, For biosimilars: FDA approval of a 351, k, application The following constitute approvals that trigger the Payout Criterion: Standard approval, traditional approval based on clinical benefit, Accelerated approval, based on surrogate endpoints, Approval with Risk Evaluation and Mitigation Strategy, REMS, Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters, CRLs, indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization, EUA, without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, X the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, Y If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, X the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, X the market will resolve based on whether the initial accelerated approval occurred after Issuance, Yes, regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, X the market will resolve to No immediately. This market will close and expire early if the event occurs.

Market Resolution Rules

Important Notes

  • Markets resolve based on official data sources specified in the rules
  • Resolution may be delayed if official data is not immediately available
  • Kalshi markets are regulated by the CFTC and follow strict resolution procedures
  • Always verify the exact resolution criteria before trading

Markets (6)

Sort
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2031, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2031, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2031. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2031, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2031, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2031, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome54.0%
Yes
Volume2.8K contracts
LiquidityN/A
End DateJan 01, 2031
View Details
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2030, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2030, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2030. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2030, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2030, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2030, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome53.0%
Yes
Volume3.5K contracts
LiquidityN/A
End DateJan 01, 2030
View Details
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2029, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2029, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2029. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2029, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2029, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2029, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome52.0%
Yes
Volume2.6K contracts
LiquidityN/A
End DateJan 01, 2029
View Details
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2032, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2032, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2032. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2032, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2032, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2032, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome51.5%
Yes
Volume2.2K contracts
LiquidityN/A
End DateJan 01, 2032
View Details
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2028?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2028?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2028, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2028. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2028, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2028, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2028, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome42.5%
Yes
Volume1.4K contracts
LiquidityN/A
End DateJan 01, 2028
View Details
KALSHIHealth
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2027?

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2027?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2027, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2027. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2027, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2027, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2027, the market will resolve to No immediately. Early close condition: This market will close and expire early if the event occurs.

Yes outcome7.0%
Yes
Volume1.3K contracts
LiquidityN/A
End DateJan 01, 2027
View Details

Share This Event

Share on social media or embed on your website